Vadadustat

Akebia Therapeutics, Vadadustat, NDA resubmission, Anemia in chronic kidney disease, complete response letter

Akebia plans to resubmit vadadustat to FDA after rejection

Anika Sharma

After facing significant setbacks, including disappointment, a partnership setback, and an FDA dispute, Akebia Therapeutics has regrouped and is poised ...